Background. Policy evaluations taking a lifetime horizon have converted estimated changes in short-term mortality to expected life year gains using general population life expectancy. However, the life expectancy of the affected patients may differ from the general population. In trials, survival models are commonly used to extrapolate life year gains. The objective was to demonstrate the feasibility and materiality of using parametric survival models to extrapolate future survival in health care policy evaluations. Methods. We used our previous cost-effectiveness analysis of a pay-for-performance program as a motivating example. We first used the cohort of patients admitted prior to the program to compare 3 methods for estimating remaining life expectancy. We then used a difference-in-differences framework to estimate the life year gains associated with the program using general population life expectancy and survival models. Patient-level data from Hospital Episode Statistics was utilized for patients admitted to hospitals in England for pneumonia
Background. Policy evaluations taking a lifetime horizon have converted estimated changes in short-term mortality to expected life year gains using general population life expectancy. However, the life expectancy of the affected patients may differ from the general population. In trials, survival models are commonly used to extrapolate life year gains. The objective was to demonstrate the feasibility and materiality of using parametric survival models to extrapolate future survival in health care policy evaluations. Methods. We used our previous cost-effectiveness analysis of a pay-for-performance program as a motivating example. We first used the cohort of patients admitted prior to the program to compare 3 methods for estimating remaining life expectancy. We then used a difference-in-differences framework to estimate the life year gains associated with the program using general population life expectancy and survival models. Patient-level data from Hospital Episode Statistics was utilized for patients admitted to hospitals in England for pneumonia T he effects of health care policies and programs should be evaluated in terms of their impact on health outcomes, as is now standard practice for all new health care technologies. This impact can be composed of effects on both the quality and length of life. Length of life is a key outcome for costeffectiveness analysis, either in isolation when calculating costs per life years gained or when combined with quality of life experienced in these years to estimate quality-adjusted life years (QALYs). This is the approach favored by governmental agencies in a number of countries including the UK, Canada, Australia, the Netherlands, and Sweden. [1] [2] [3] In this article, we focus on the methodology for estimating the impact on length of life.
As full survival data are rarely available, the evaluation problem faced can be broken down into 2 key aspects: estimating the effect of the policy on mortality, and evaluating the long-term gains in life years associated with this effect on mortality. [4] [5] [6] Policy evaluations attempting to take a lifetime horizon can use administrative data sets to estimate changes in short-term mortality and subsequently convert these to projected gains in life years using published estimates of life expectancy for the general population. Examples include measuring National Health Service (NHS) productivity, 7, 8 estimating the National Institute for Health and Care Excellence (NICE) decision threshold, 9 and analyzing the cost-effectiveness of pay-for-performance programs. 10 The approach taken in previous work has been to estimate the impact of a program in terms of changes in the probability of mortality within 30 days, assessed as a binary outcome. 7, 8, 10 Estimated reductions in this mortality rate are then translated into life years gained. Patients dying within 30 days are effectively assumed to die instantly and attributed no survival days in this calculation, while those surviving past 30 days are assigned the remaining age/gender-specific life expectancy of the general population.
These published estimates of life expectancy at particular ages are calculated from mortality rates observed in the general population. Although they appear to be projections, life expectancy figures are in fact a summary statistic of cross-sectional age-specific mortality rates. Life expectancy figures therefore represent the average length of life of a hypothetical cohort of individuals exposed for each of their remaining years to the age-specific annual mortality rates experienced by the general population who were alive at the start of a reference period. Life expectancy is positive at each age, and the implied length of life (years lived so far plus remaining life expectancy) increases with age. Thus, while life expectancy at birth is 83 years for females in England, life expectancy for those who survive to age 83 years is 8 years. 11 The length of life of the patients affected by health care policies and programs is, however, likely to differ from that of the general population. This may lead to incorrect estimations of the effects on life years gained as a result of any reductions in mortality rates. The true impact of such programs on survival may also be more complex, with changes to health care initiatives having the potential to impact survival over the whole life course. These longer term effects are not captured in evaluations focusing solely on mortality rates within the short-term windows normally assessed. Even with the minimal data of 1 financial year available in many administrative data sets, it is possible to observe the majority of patients for longer than the standard period of 30 days, unless they are treated during the last month of the period. This enables the observation of these patients for an additional 1 to 334 days, depending on when in the year they entered treatment. This prolonged follow-up information has, however, often been ignored in policy evaluations to date.
When analyzing data from clinical trials, survival models are commonly used to extrapolate gains in life expectancy from the observed trial data. 12, 13 Such analysis utilizes all available follow-up information on patients rather than applying an arbitrary cutoff window. In this article, we examine whether the additional information available within administrative data sets on survival beyond the usual 30 days considered, albeit censored, can be used to improve the accuracy of estimated life years gained in policy evaluations. The aim of this article is to demonstrate the feasibility and materiality of using parametric survival models commonly employed in clinical trials analysis to extrapolate future survival for use in health care policy evaluations.
METHODS
We used our previous cost-effectiveness analysis of the first 18 months of the Advancing Quality (AQ) pay-for-performance program as a motivating example. 10 AQ is a quality improvement initiative, supported by financial incentives, introduced to all of the 24 hospitals in the North West of England in October 2008 (see Meacock and others, 10 Sutton and others, 14 Kristensen and others, 15 and McDonald and others 16 for a full description of the policy). We previously estimated that the introduction of AQ led to a 1.6 percentage point reduction (95% CI = 22.4 to 20.8) in the rate of mortality within 30 days of admission to a hospital for pneumonia. 10 This reduction in mortality was then translated into an estimated gain of 4701 QALYs by applying published estimates of life expectancy from the general population, which were adjusted for quality of life and discounted.
In our previous analysis, we considered all patients admitted for pneumonia in England over a 3-year period, including 18 months before the program was introduced and the first 18 months of its operation. In this article, we consider, for simplicity, a more typical situation in which data on dates of admission and death are available for 1 financial year prior to the introduction of the program and 1 financial year following its implementation.
We used parametric survival models to estimate the effect of AQ on survival among the affected population over a lifetime horizon. These results were compared to those obtained by estimating the impact of the policy on mortality 30 days after admission and applying general population life expectancy estimates to this short-term mortality change. We restricted the analysis to patients admitted in an emergency with pneumonia using International Classification of Diseases 10th Revision (ICD-10) codes for the rules specified for the AQ scheme. i Secondary ICD-10 diagnosis codes were used to identify patients with Elixhauser conditions, 18 which were used to risk-adjust our estimates in conjunction with information on the primary diagnosis, age, gender, financial quarter of admission, hospital trust, location from which a patient was admitted (own home or institution), and type of admission (emergency or transfer). 19, 20 
Comparison of Methods on a Development Cohort
We first used the cohort of patients admitted to any hospital in England prior to the introduction of AQ (1 April 2007 to 31 March 2008) to compare 3 methods for estimating the remaining life years of the population using data from this financial year only. We then compared the predicted survival to the observed data on the survival of the cohort up to 31 March 2011.
The purpose of this initial analysis was to illustrate the difference in the magnitude of the estimated remaining life years of a patient population when the additional information available on survival past 30 days is utilized and information on the risk of death is taken from the population under investigation rather than general population figures. In addition, this exercise was used to select the most appropriate functional form for the survival models to be used in the later evaluation of AQ.
Simple application of published life expectancy tariffs (method i)
We started by applying a simplified version of the method used in our original analysis of the program in which mortality occurring within 30 days of admission is defined as a binary outcome. 10 This method is simplified here in that it does not incorporate quality of life adjustments or discounting and closely resembles that applied in other policy evaluations. [7] [8] [9] Gender-specific life expectancy estimates at each single year of age from age 18 to 100 years were taken from the 2008 to 2010 interim life tables from the ONS 11 and attached to patients surviving beyond this 30-day period to estimate their remaining life expectancy:
where s 30 i equals 1 if individual i survives more than 30 days and 0 otherwise, and L ga is the life expectancy of an individual of gender g who is currently aged a.
This method implicitly assumes that individuals surviving beyond 30 days after admission survive, on average, the life expectancy of the general population of the same age and gender. This will produce an inaccurate estimate of the actual life expectancy for 2 reasons: 1) the period of survival within 30 days is not incorporated into the estimate, and 2) it assumes that the life expectancy of individuals who survive past 30 days after admission will be equal to that of the general population of their age and gender.
Moreover, this method ignores information on observed survival available within the data set beyond the period of 30 days after admission.
Short-term observed survival plus application of published life expectancy tariffs (method ii)
We then extended this method to utilize all of the information on mortality available within the year of data (1 April 2007 to 31 March 2008) as we could follow patients for between 1 and 365 days depending on their admission date. For those who died during the period, the number of days survived between the date of admission and the date of death is used. Age-and gender-specific estimates of life expectancy were again applied to all patients who remained alive at the end of the observed data period:
where s tÃ i is a binary indicator equal to 1 if individual i survives to the end of the observation period t Ã , t y i is the date of death for individuals who die before the end of the observation period, and t 0 i is the date of admission. This improves on the original method by eliminating problem 1 and reducing, but not eliminating, inaccuracies due to problem 2.
Extrapolation using survival models (method iii)
Finally, we improved the method used for extrapolation beyond the observed period by estimating parametric survival models on the observed 1 year of data. These survival models were then used to predict lifetime survival based on the mortality rates of the population of interest observed during this period.
Six standard parametric models were considered (exponential, Weibull, Gompertz, log-logistic, lognormal, and generalized gamma). The fit of these 6 different models to the observed data was assessed using the Akaike information criterion (AIC), tests of whether restrictions on the parameters in the generalized gamma model suggest that it could be reduced to the simpler models that it nests and examination of residual plots, in accordance with the recommendations made by Latimer. 13 The external validity of the extrapolations produced was then assessed by comparing the proportion of the cohort predicted to be alive at annual intervals to the observed survival now available to 31 March 2011.
The risk-adjustment covariates listed in the data section (primary diagnosis, secondary diagnosis, single year of age interacted with gender, financial quarter of admission, hospital trust, location from which a patient was admitted [own home or institution], and type of admission [emergency or transfer]) were included in all of the survival models in the scale parameter using the ''streg'' command in Stata (StataCorp, College Station, TX). The addition of covariates to the shape parameter(s) for models other than the exponential was explored but did not improve model fit. The shape parameters in all of the models are therefore estimated directly, while the scale parameters are estimated as a linear function of the covariates listed.
Our early investigations showed that while standard parametric models were able to fit the observed data well, the tails of these distributions did not correctly represent the pattern of future mortality. This is because the hazard rates experienced by our patient cohort change over time, with the extremely high-risk period shortly after an emergency hospital admission not representative of the lifetime risk of those surviving past this period.
As a result, we estimated survival in 2 separate models: one for the short term and one for the longer term. Short-term survival during the first year was estimated on the observed 1 year of data. The extrapolation of long-term survival was based on a model estimated on data excluding the first 30 days following admission. 12, 21 These long-term models represent the hazards experienced by our patient cohort after the initial high-risk period following an emergency hospital admission. These are still much larger than those experienced by the general population but are significantly lower than when they were first admitted to the hospital.
This approach bears some similarities to that suggested by Gelber and colleagues 22 in that survival is divided into the short term and the tails of the distribution which are fitted separately, but here, we fitted a parametric model to the short-term data rather than simply using the observed Kaplan-Meier curve. This allowed us to estimate the effect of covariates on survival in both the observed and extrapolated periods.
Following the estimation of the survival models, we created additional rows of data for each individual for each possible future year up to the age of 100 years. We estimated the probability of surviving to that year, allowing for the progression of time and increments in age. This approach is analogous to the estimation of transition probabilities in a Markov model:
wherem t i is the probability that individual i will die by time t, given that they have survived to time t -1, and s it is the probability that individual i will survive to time t, given the values of their covariates x and their age of a i at the time of their admission. We estimated the probability of dying during the first year (m 1 ) using all data on survival following the admission date (short-term model) and the probability of dying in subsequent years (m t ) using the data on survival following 30 days after the admission date (long-term model).
We then calculated the individual's life expectancy using the sum of the probability of surviving to the end of the first year and the survival rates for each subsequent year up to the maximum age of 100 years:
where L i is the life expectancy of individual i,m 1 i is the probability that individual i will die by the end of the first year, t Ã À t 0 i is the length of time between the individual's admission date and the end of the first year, A is the maximum age (100 years), and the summation is over products of the probability of surviving to the start of each subsequent year and the probability of surviving that subsequent year, given that the individual will have aged by those subsequent years.
This method again eliminates problem 1 (the period of survival within 30 days not being incorporated into the estimate) and further reduces inaccuracies due to problem 2 (previously assuming that the life expectancy of individuals who survive past 30 days after admission will be equal to that of the general population of their age and gender) by using information on the mortality rates of the population under study to estimate their future survival. We compared the results given at each of these 3 stages, as the original assumptions were dropped and improved on, to illustrate the materiality of these developments to our estimates of life years remaining.
Application to the Evaluation of AQ
Having demonstrated the use of parametric survival models, and the materiality of the difference that this makes to the estimated life years remaining for our patient cohort, we illustrate how these models can be used in an applied program evaluation. We considered a dichotomous differencein-differences design in which outcomes were observed for treated and control units before and after the introduction of the program:
where L ijt is the life expectancy of individual i treated in hospital j at time t, f Á ð Þ is the link function, X is the vector of case-mix covariates, u j are provider fixed effects, v t are time fixed effects, D 1 j is a dummy variable taking the value 1 for hospitals that become part of the AQ program, D 2 t is a dummy variable taking the value 1 in the periods after the introduction of the AQ program, and e ijt is an individual-specific error term. d is the difference-in-differences term, which is our coefficient of interest.
We first considered the situation outlined above in which data on dates of admission and death were available for 1 financial year prior to the introduction of the program (1 April 2007 to 31 March 2008) and 1 financial year following its implementation (1 April 2009 to 31 March 2010). An additional advantage of using survival analysis, however, is that the additional follow-up data on the preintervention group collected during the same period as the initial follow-up of the postintervention group can be utilized. We therefore examined how the life expectancy estimates were affected when including the additional follow-up available (1 April 2008 to 31 March 2010) on the group admitted prior to the intervention, so that this group was now followed up for a maximum of 3 years. In principle, utilizing this additional available information on the preintervention population should improve the accuracy of our estimates of long-term survival and the estimated impact of the program.
To calculate the effect of the program on life expectancy, we used average partial effects. We estimated life expectancy for the individuals admitted to AQ hospitals in the post-AQ period under 2 scenarios, with the difference-in-differences term set to 1 and to 0. These represent our estimates of the life expectancy of these patients in the presence and absence of the policy, respectively.
These results were compared to those obtained by estimating the impact of the policy using linear regression on general population life expectancy estimates attached to individuals who survived 30 days after admission. Finally, we performed a sensitivity analysis using the second best-fitting parametric model to estimate the impact of the policy on life expectancy to illustrate the impact of model selection on these estimates.
RESULTS

Development Cohort
The characteristics of the patient cohort are presented in Table 1 and discussed in more detail below when we describe the application of our method to AQ. The annual mortality rates by age and gender for this patient cohort were considerably higher than those experienced by the general population (Table 2) , illustrating the importance of using information on the risk of death from the population under investigation rather than general population figures when estimating remaining life years. Using general population figures would lead us to underestimate the annual mortality rate experienced by our population by a factor of between 2 (age .100 years) and over 300 (age 20 years). Figure  1 shows the Kaplan-Meier survival curve for these patients over the period from 1 April 2007 to 31 March 2008 and highlights the high rate of mortality in the initial high-risk period following an emergency admission.
A comparison of the performance of the 6 parametric survival models showed that the generalized gamma distribution gave the lowest AIC, followed by the log-normal distribution ( Table 3) . A Wald test confirmed that the generalized gamma distribution does not reduce to a log-normal distribution in this case (P \ 0.001). A visual inspection of Cox-Snell residual plots also supported the use of the generalized gamma distribution (not shown). Finally, the generalized gamma distribution gave the best performance on the external validity assessment, predicting the proportion of the cohort alive to within 1% of the observed survival rate at each of the 4 annual time points now available in the prolonged follow-up data ( Table 3) . A generalized gamma distribution was therefore chosen to model survival. The life expectancy of the cohort of 113,289 patients admitted during 2007/2008 was estimated using the 3 different methods (Table 4 ). Twenty-seven percent of the cohort died within 30 days and were therefore assigned no life expectancy under method i. The remaining 73% surviving past this point were assigned life expectancy estimates from the general population. This approach estimated that the cohort had, on average, 13.15 years of life remaining.
When taking into account additional information on survival past 30 days to the end of the financial year, a further 12% of the initial cohort was observed to have died during this period. The impact of using this additional available information on survival past 30 days was to reduce the estimate of average life years remaining from 13.15 years to 11.98 years. This estimate, however, still assumes that patients surviving to the end of the financial year under observation will experience, on average, the life expectancy of the general population of their age and gender.
Finally, this assumption was relaxed when we used parametric survival models with a generalized gamma distribution to predict life expectancy based on the rates of mortality observed within the cohort. This method further reduced our estimate of the average number of life years for the cohort to 9.19 years.
In this development cohort, taking into account the additional information available on survival past 30 days reduced the estimate of average life expectancy by 9%. Once survival models were used (Table 1) . Patients admitted to hospitals in the North West of England before the introduction of AQ were slightly younger than their counterparts in the rest of England (71.7 v. 72.2 years, respectively) and had a higher number of coexisting conditions (1.79 v. 1.65, respectively). The unadjusted mortality rate within 30 days of admission was higher in the North West than in the rest of England (28.4% v. 27.3%, respectively). This difference in mortality persisted in the longer term, with 40.7% of the cohort admitted to hospitals in the North West having died by the end of the financial year versus 38.6% of those admitted in the rest of England.
During the period from 1 April 2009 to 31 March 2010, 19,946 patients were admitted for pneumonia to hospitals participating in the AQ program, and 106,365 were admitted to hospitals in the rest of England that did not participate in AQ. Patients admitted to hospitals in the North West were again slightly younger than their counterparts in the rest of England (71.9 v. 72.8 years, respectively), with a higher number of coexisting conditions (1.99 v. 1.92, respectively). The unadjusted mortality rates decreased in both regions during our evaluation period, with a greater reduction in the North West than the rest of England. The rate of mortality within 30 days of admission was lower in the North West than the rest of England in this period (25.6% v. 26.0%, respectively), with no difference in the proportion of patients still alive at the end of the financial year (37.3% died in both regions). These figures illustrate the positive effect of the program on reducing mortality rates within 30 days of admission found in our previous evaluation. 10 Table 5 shows the estimated effect of AQ on remaining life expectancy for patients admitted in the North West in 2009/2010. An ordinary least squares (OLS) difference-in-differences regression of the general population life expectancy figures applied to those surviving past 30 days after admission (method i) estimated that AQ led to an average increase in remaining life expectancy of 0.154 years. The remaining life expectancy of the patient cohort was estimated to have been 13.22 years in the presence of AQ and would have been 13.06 in the absence of the policy.
An OLS difference-in-differences regression of the general population life expectancy figures now applied to those surviving past the end of the financial year (method ii) produced a larger treatment effect estimate of AQ on average life expectancy of 0.221 years. This is despite lower estimates of remaining life expectancy of the patient cohort both in the presence (11.98 years) and absence of AQ (11.76 years). These lower absolute estimates of remaining life expectancy are expected as they account for the additional deaths that we are able to observe using the extended follow-up to the end of the financial year. The increase in the estimated effect of AQ on life expectancy indicated that the policy impacted on survival beyond the 30-day postadmission window usually assessed.
In the parametric survival models utilizing mortality information until the end of the financial year, the coefficient on the difference-in-differences term was negative and statistically significant. The generalized gamma distribution was parameterized in the accelerated failure time (AFT) metric, meaning that coefficients of \1 indicate that time passes more slowly and so failure (death) would be expected to occur later as a result of AQ. This estimated effect on the failure time translated into an average estimate of 9.04 remaining life years of the cohort in the presence of the policy and 8.73 in its absence. These reductions in both estimates of average life expectancy compared to the estimates from the OLS models were again as expected, as we now used information on the mortality rates observed among the patient population rather than general population life expectancy estimates. Nevertheless, this translated into a larger estimated treatment effect of AQ of 0.311 years, suggesting that AQ had a prolonged impact on survival past the end of the financial year assessed.
We then estimated survival models utilizing the additional data available on follow-up for the preintervention group to the end of our evaluation period (data window from 1 April 2007 to 31 March 2010) to inform our estimates. This additional data increased the precision of our estimates, with the treatment effect of AQ now estimated to be 0.380 years. Utilizing this additional data slightly decreased the estimated remaining life expectancy for the cohort both in the presence and absence of the policy (8.439 v. 8.059 years, respectively) but further increased the estimated effect of AQ on the 
Patients admitted after AQ life expectancy of patients admitted to hospitals in the North West during the treatment period. Finally, we present a sensitivity analysis using the log-normal distribution ( Table 6 ). This analysis produced very similar results to that using the generalized gamma distribution over the same data period. The log-normal distribution was again parameterized in the AFT metric, meaning that coefficients of \1 are associated with a deceleration of time to death. The remaining life expectancy of the patient cohort admitted to hospitals in the North West after the policy was introduced was estimated to be 9.284 years in the presence of AQ and 8.971 years in its absence. This resulted in an estimated treatment effect attributable to AQ of 0.313 years. In this instance, the choice of distribution used to model survival had little impact on the treatment effect estimates.
DISCUSSION
Policy evaluations attempting to take a lifetime horizon have used administrative data sets to estimate changes in short-term mortality and subsequently converted these to projected gains in life years using published estimates of life expectancy for the general population. This may lead to inaccurate estimates of the effect on life years gained if the length of life of patients affected by the health care program differs from that of the general population or if the policy affects survival over the whole life course rather than just during the evaluation period.
While statistics such as mortality occurring within 30 days of admission are a useful indicator of a program's success, information on the impact over the lifetime horizon of the affected patients is needed to inform decisions regarding cost-effectiveness. We have demonstrated the feasibility of using parametric survival models commonly employed in clinical trials analysis to extrapolate future survival in health care policy evaluations. Our application of these methods to the AQ initiative reinforces the importance of both using the mortality rates observed in the patient population under study rather than taking estimates from the general population and utilizing all available follow-up data on survival. We have demonstrated the impact that this has on the estimates of both the remaining life years of a patient cohort and the treatment effect of the policy under investigation. In a cohort of patients admitted to hospitals for pneumonia during 1 financial year, the estimated mean life years remaining was 30% lower when parametric survival models were used compared to the traditional method of applying general population life expectancy estimates to those surviving more than 30 days past admission. When assessing the predictive accuracy of our chosen survival model against the further 3 years of follow-up data now available, predictions of the proportion of the cohort alive at 4 annual intervals were within 1% of the observed survival rate, supporting the accuracy of this method.
However, when survival analysis was used to estimate the effect of the AQ program on the survival of the patients treated, this produced a larger estimated treatment effect than the traditional method. This suggests that AQ impacted on survival past the 30-day postadmission window usually assessed. The ability of survival models to capture the effect of a policy over the whole life course of the affected patients is another advantage of using this method. Nevertheless, we acknowledge that even extrapolations based on extended followup may still provide inaccurate predictions, as illustrated by Davies and others. 23 A conservative approach to extrapolation is therefore recommended, fitting and testing a range of survival models to assess both their internal and external validity. While overcoming the assumption of general population life expectancy, parametric modeling introduces new assumptions that must be considered.
In addition to following the useful guidance on survival analysis published by Latimer, 13 there are some further considerations for researchers performing program evaluations using administrative data rather than health technology assessments of single interventions from randomized controlled trials. A first step should always be a comparison of the observed mortality rates of the patient population under consideration to those experienced by the general population. If the mortality risk is only apparent in the very short term, and longer term survival rates are similar to those experienced by the general population, then survival analysis may not be needed.
If, as in the case of our evaluation, the mortality rates of the patient population are significantly different to the general population, various survival models should be assessed. In a preevaluation and postevaluation design, survival models can be developed on the preintervention population and their predictive performance evaluated against the observed follow-up available on these patients during the postintervention period to assess the external validity of the models developed. All available follow-up data on the preintervention group can then be utilized to inform the baseline pattern of survival and increase the accuracy of the estimated treatment effect of the program in question. If modeling short-and long-term survival separately as done here, a simple histogram of events over time can be informative in selecting the cut-off point at which data are excluded when fitting the long-term models to extrapolate. The tradeoff between the loss of follow-up data utilized and the exclusion of shortterm event rates not representative of long-term survival must be considered and will largely depend on the length of follow-up available.
Limitations and Directions for Future Work
The purpose of this article is to demonstrate how survival analysis can be applied beyond the setting of randomized controlled trials in order to extrapolate survival for use in cost-effectiveness analysis of health care policies and programs using administrative data sets. In order for the estimates of life years gained calculated here to be used in a cost-effectiveness analysis, the stream of remaining life years for each patient under evaluation would also need to be adjusted for quality of life and discounted to present day values to calculate the effect of AQ in terms of QALYs. These extensions are simple to perform, as demonstrated in our previous evaluation. 10 The large scale of administrative data sets such as that used here could also offer a useful source for researchers wishing to develop and refine further methodological advances in survival analysis. Unlike randomized controlled trials, administrative data can often allow researchers to capture the entire affected population of interest in a real-life treatment setting and so enable an externally valid evaluation of the effect of the policy or program change in question. The scale of these data sets and amount of additional information that they contain have the potential to enable accurate estimates of survival using minimal follow-up.
We found that previously employed methods used to estimate the impact of health care policies over a lifetime horizon led us to overestimate the remaining life expectancy of our cohort but underestimate the impact of the policy in question on this life expectancy. The application of survival analysis utilizing minimal additional, but readily available, data on prolonged follow-up considerably improved the accuracy of our estimates of both absolute survival and the impact of the AQ program on the survival of the targeted patient population. There are many national administrative data sets available for use in similar analyses such as Hospital Episode Statistics in England, 24 insurance claims databases in America, and linked administrative data sets in Canada. 25 We hope that the methods demonstrated here will be further developed and applied using these data sets to improve the accuracy of future costeffectiveness analyses of health care policies and programs. 
